

Our Executive Team

Olympus is focusing on realizing Our Purpose with patient safety as the top priority. On the following pages, we introduce Executive Officers who are driving the execution of our company strategy to become a leading global MedTech company.

Yasuo Takeuchi

Director,
Representative Executive Officer,
Executive Chairperson and
ESG Officer



Bob White

Director,
Representative Executive Officer,
President and
Chief Executive Officer



John de Csepel

Executive Officer and
Chief Medical Officer



Responsibility

Responsible for operations related to medical affairs*1

Key initiatives for FY2026

Clinical Affairs:

- Expand use of non-traditional evidence-generating methods such as real-world evidence, clinical registries and collaborative research
- Realize efficiencies with the implementation of new global clinical trial and grant management platforms

Medical Affairs:

- Enhance our medical director team by adding world-renown Pulmonary and Gastroenterology clinical leaders
- Utilize our medical directors to identify unmet clinical needs and contribute to strategy formation and the assessment of new product ideas and potential company acquisitions

Health Economics and Market Access (HEMA):

- Accelerate commercial success by expanding coverage for iTind
- Respond to the institution of market access challenges in China including volume-based purchasing and DRG payments with novel solutions by differentiating through the promotion of medical value

Professional Education:

- Expand HCP training activities in the emerging markets
- Continue expansion of the Olympus Continuum digital training platform

Medical Safety:

- Harmonize medical safety efforts across Olympus' five regions*2
- Continue to support the quality and regulatory transformation project *Elevate*

Frank Drewalowski

Executive Officer and
Gastrointestinal Solutions



Responsibility

Responsible for operations mainly in the Gastrointestinal Solutions Business

Key initiatives for FY2026

GI Endoscopy:

- Start Phase 2 of EVIS X1 U.S. launch with differentiated Extended Depth of Field (EDOF) scope line, providing high magnification and broad focus for easier tissue identification
- Continue targeted approach of expanding market share in emerging markets
- Expedite go-to-market execution for localized GI Endoscopy production in China.
- Drive coordinated launch of expanded endoscopic ultrasound platforms with the Aplio (Canon Medical Systems partnership) and EU-ME3 systems
- Launch of initial OLYSENSE*3 products in Europe and U.S. in FY2026

GI EndoTherapy:

- Expand clinically differentiated product offerings in ERCP, ESD, Luminal Patency (Metal stent), and Hemostasis
- 10+ product launches regionally including key markets: U.S., Europe, and Japan

Medical Service:

- Industry-leading services built around customer needs of uptime, budget security and operational support
- Tight integration of service and repair for highly efficient, customer-focused delivery

*1 Medical & Scientific Affairs (MSA) ensures the safety, efficacy, and innovation of medical devices while driving patient-focused value and expanding healthcare access. Through Clinical Affairs, Medical Affairs, Healthcare Economics, Medical Safety, and Professional Education, MSA supports Olympus' growth by addressing clinical needs, regulatory & reimbursement barriers, and physician awareness and training.

*2 The Americas, EMEA, Japan, China, and APAC

*3 OLYSENSE is a trademark of Olympus Corporation and/or its affiliated entities. All trademarks, logos and brand names are the property of their respective owners.

Tatsuya Izumi

Executive Officer and Chief Financial Officer



Responsibility

Responsible for operations related to finance, spend control for Olympus group, and investor relations

Key initiatives for FY2026

Focus on Balancing Sustainable Business Growth with Operational Efficiency:

- While securing investments in innovation essential for growth, manage SG&A expenses to ensure their growth remains below the revenue growth rate by optimizing other spending
- Provide timely and appropriate financial information to business units and support management initiatives that emphasize efficiency
- While prioritizing continuity in Medical Business, maintain appropriate inventory levels to mitigate the impact on cash flows
- Contribute to enhancing corporate value through interactive communication with capital markets
- Establish a management control system centered on business divisions
- Support to mitigate the impact of U.S. tariff policies and the U.S. Food and Drug Administration (FDA) Import Alerts from a financial perspective

Gabriela Kaynor

Executive Officer and Chief Strategy Officer



Responsibility

Responsible for taking care of corporate strategy, enterprise level transformation efforts, information technology, corporate communications and alignment across our Regional Representative Officers

Key initiatives for FY2026

- Development of our next corporate strategy
- Strong communication and change management plans to align all levels of the organization around key strategic priorities
- Strong governance to deploy investment and resource allocation in support of our strategic ambition and priorities
- Global monitoring of key performance indicators (KPIs) around our key strategic initiatives to drive execution and accountability
- Advance global target operating model towards a customer-centric simplified operating model in support of our strategic ambition
- Integrate enterprise-level roadmap of business process, capabilities, tools and enablers in support of sustainable growth
- Improve efficiency and effectiveness of the Group Executive Committee

Tetsuo Kobayashi

Executive Officer and Chief Manufacturing and Supply Officer



Responsibility

Responsible for managing and operating the manufacturing, procurement, and supply chain functions

Key initiatives for FY2026

- Drive Design for Excellence (DfX) initiative together with R&D, to upgrade our product architecture with the inputs from a manufacturing, repair, and quality point of view
- Drive digital transformation to upgrade our end-to-end supply chain in future operations
- Optimize and future-proof operations footprint to unlock further business potential and sustained build-up of resilience
- Successfully start production in China to support further business growth
- Enhance supplier Business Continuity Planning (BCP) and cost optimization in driving global category management strategy
- Successfully complete all the FDA commitment in each manufacturing plants, and keep strengthening quality management system.
- Promote more cross-functional synergy & excellence opportunities as ONE CMSO to drive more operational efficiency and resilience

Seiji Kuramoto

Executive Officer and Surgical and Interventional Solutions



Responsibility

Responsible for operations mainly in the Surgical Interventional Solutions Business

Key initiatives for FY2026

Urology:

- Expand leadership in benign prostate hyperplasia (BPH) through iTind market development while increasing penetration of the core visualization and PLASMA technologies
- Drive lithotripsy growth through the SOLTIVE SuperPulsed Laser System

Respiratory:

- Drive growth in lung cancer diagnosis and staging with stronger emphasis around updated EBUS-TBNA offering
- Reinforce strength in respiratory endoscopy through continued focus on driving adoption of the EVIS X1 bronchoscopy platform

Surgical Endoscopy:

- Introduce the VISERA ELITE III surgical endoscopy system in the U.S. and China (FY2026 1Q) to improve market competitiveness

Syed Naveed

Executive Officer and Chief Technology Officer



Responsibility

Responsible for leading the development of the group-wide technology strategy, ensuring competitive products and services based on company strategy and the latest technology and innovation trends, and overseeing the securing of market launch plans for new products

Key initiatives for FY2026

Drive Transformational Innovation:

- Drive the development of next-generation minimally invasive medical solutions by integrating and evolving innovative technologies such as robotics, digital technology, and artificial intelligence (AI)
- Enhance collaboration with healthcare professionals to provide meaningful solutions that prioritize patient safety and quality

Enhance Productivity and Speed in New Product Development:

- Optimize the R&D process for new product development to improve development efficiency, stabilize quality, and reduce costs

Optimize Global R&D Footprint to Enhance Scalability:

- Expand offshore development capabilities in India and China to accelerate and streamline the market launch of new products

Acquire and Strengthen Key Capabilities and Skills:

- Strategic advancement of talent management and capability enhancement related to core expertise

Foster Healthy Organizational Culture:

- Cultivate an open culture and growth mindset to build a strong R&D organization

Shigeto Ohtsuki

Executive Officer and Chief Human Resources Officer



Responsibility

Responsible for managing and operating the human resources functions, including operations for talent management, talent development, and workplace environment

Key initiatives for FY2026

Advance Talent Strategy:

- Rebuild long-term talent strategies (talent development and management) and formulating succession plans for the executive team

HR System Reform:

- Design a globally unified HR system, strengthen system operations through additional IT system implementations, and ensure penetration of the system in Japan

Redesign Organizational Structure:

- Create a simple and optimized organization globally

Transform Corporate Culture:

- Cultivate a new corporate culture aligned with the Company's strategic transformation
- Complete initiatives to strengthen quality assurance and regulatory affairs (QA&RA)

Enhance ESG Programs:

- Advance carbon neutrality through the adoption of renewable energy
- Execute advanced initiatives to further promote inclusion

Boris Shkolnik

Executive Officer and Chief Quality Officer



Responsibility

Responsible for overseeing and driving the development and implementation of global quality and regulatory strategies to ensure compliance, enable regulatory approvals, and support product safety, patient outcomes, and business growth through effective leadership of quality, risk management, and performance improvement initiatives

Key initiatives for FY2026

FDA Warning Letter Resolution:

- Achieve closure of the FDA warning letters and strengthen global compliance by advancing quality system maturity, completing remediation efforts, and ensuring inspection readiness across all FDA-registered sites

Enable Rapid Innovation and Business Growth by:

- Develop and implement a robust due diligence and integration process for M&A
- Streamline and accelerate global regulatory clearances
- Quality management system (QMS) operating model: Develop a long-term QMS design model and initiate transition from the current state

Focus on Outcomes:

- Drive the stabilization of quality performance through management review and quality scorecard processes, foster a strong safety and quality culture, and ensure disciplined execution aligned with strategic and financial objectives

Neil Boyden Tanner

Executive Officer and Global General Counsel



Responsibility

Responsible for overseeing global operations related to legal affairs, intellectual property, compliance and risks/controls, including promoting legal compliance, managing legal risks, and advising on corporate governance matters. Act as a strategic advisor to the board and executive team, guiding the Company through complex legal landscapes and contributing to achieving its overall business strategy

Key initiatives for FY2026

- Streamline support by enhancing the business partner framework to achieve growth goals
- Continue to align our intellectual property work to our CTO and business strategy
- Mitigate risks through enhanced global policies, monitoring and training programs
- Continue to strengthen our cyber resiliency including the incorporation of "Privacy by Design" in product development processes
- Optimize contract processes and leverage technology to advance commercial goals
- Strengthen internal systems to elevate third party risk management
- Simplify our global legal entity structures, create simplified executive governance and integrate Enterprise Risk Management (ERM) into key strategic initiatives
- Continue to assess the risks of AI systems, including creating an AI Governance policy and GenAI training
- Continue to drive cost reductions through improved outside vendor management